A Pilot, Exploratory, Randomized, Phase II Safety Study Evaluating Tumor Cell Mobilization and Apheresis Product Contamination in Patients Treated with Granulocyte Colony-Stimulating Factor Alone or Plus Plerixafor

Autologous transplantation of hematopoietic stem cells (HSCs) is a widely used strategy for hematologic and immunologic recovery after high-dose chemotherapy for hematologic malignancies, such as multiple myeloma (MM), non-Hodgkin lymphoma, Hodgkin disease, and other cancers, including germ cell tumor and neuroblastoma [1]. After chemotherapy induction, regardless of whether or not the chemotherapy has been accompanied by cytokine (usually granulocyte colony stimulating factor [G-CSF]) treatment, or after the patient has received treatment with a cytokine alone (such as G-CSF) without associated chemotherapy, HSCs for transplantation are usually obtained from the peripheral blood.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research